Skip to main content
. 2021 Apr 23;14:477–485. doi: 10.2147/PGPM.S291723

Table 4.

Pharmacokinetic Parameters According to Sex, Mode of Administration and Polymorphisms in the Fed Study

Number AUC0-∞/DW(kg*h*ng/mL*mg) Cmax/DW(kg*ng/mL*mg) Tmax(h) t1/2(h) Vd/F(L/kg) CL/F(L/h*kg)
Sex
Female 6 416.13(95.34) 39.11(10.17) 6.63(2.04) 8.60(1.22) 30.38(3.49) 2.51(0.59)
Male 31 555.76(173.21) 59.69(21.05)* 4.77(1.28)* 9.71(1.33) 28.16(12.81) 2.01(0.85)
Mode of administration
C 18 525.06(195.05) 55.39(22.24) 4.97(1.26) 9.68(1.16) 30.94(15.64) 2.22(1.06)
D 19 540.75(148.04) 57.26(20.40) 5.17(1.82) 9.39(1.54) 26.22(5.98) 1.97(0.51)
CES1.rs2244613.c.1165.33C.A
GG 16 508.14(131.22) 54.01(16.73) 5.30(1.78) 9.28(1.22) 27.90(7.70) 2.09(0.52)
GT 15 527.16(184.66) 51.85(20.56) 5.21(1.49) 9.51(1.06) 30.02(16.13) 2.19(1.10)
TT 6 614.61(226.94) 73.83(26.80) 4.15(0.67) 10.26(2.19) 26.39(9.02) 1.85(0.78)
CES1.rs8192935.c.257.885T.C
AA 22 496.51(177.32) 50.96(18.93) 5.30(1.56) 9.18(1.22) 30.36(14.31) 2.30(0.98)
AG 11 541.84(102.78) 56.31(17.17) 5.11(1.68) 9.67(0.82) 26.64(5.96) 1.90(0.34)
GG 4 710.44(201.27) 86.12(20.61)* 3.78(0.34) 11.05(2.34)* 23.52(6.75) 1.50(0.46)
ABCB1.rs1045642.c.3435T.C
GG 13 568.80(165.51) 66.00(20.12) 4.25(0.73) 9.79(1.67) 26.02(5.77) 1.88(0.47)
AG 16 492.45(183.68) 47.37(19.48) 5.66(1.95)* 9.70(1.25) 32.70(15.97) 2.34(1.07)
AA 8 556.46(151.83) 58.62(20.14) 5.25(1.15) 8.78(0.73) 24.21(6.28) 1.94(0.63)
ABCB1.rs4148738.c.2482.2236G.A
TT 14 568.68(159.39) 62.13(21.00) 4.41(0.84) 9.77(1.63) 25.85(5.32) 1.87(0.45)
CT 18 502.83(193.15) 51.36(21.53) 5.58(1.94) 9.57(1.25) 31.86(15.58) 2.32(1.07)
CC 5 542.59(105.28) 58.11(18.65) 5.10(0.91) 8.72(0.49) 23.95(5.19) 1.90(0.39)
ABCB1.rs2032582.c.2677T.A.G
AA 6 504.08(133.29) 53.20(20.57) 5.48(1.23) 8.53(0.64) 25.81(6.51) 2.12(0.64)
AC/AT 17 514.08(192.92) 52.70(21.41) 5.48(1.95) 9.69(1.19) 31.67(16.04) 2.27(1.08)
CC/CT/TT 14 568.68(159.39) 62.13(21.00) 4.41(0.84) 9.77(1.63) 25.85(5.32) 1.87(0.45)

Notes: Data are shown as mean (SD). *P< 0.05 after an ANOVA or t-test.